TrialDiabetes, obesity & metabolism2026

Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.

Elif I Ekinci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.